# Damora Therapeutics (DMRA.US)

Canonical: https://gigainvestors.com/s/DMRA

Analysis as of: 2026-10-16T07:28:03.694Z. Financial observations: FY2018–FY2025.

Listing currency: USD. Reporting currency: USD.

## Verdict

Not a wonderful business

Quality tests for Buy: not passed (profit record: fail; earnings resilience is evidence only). Published buy qualification: no.

Share price: $18.74 per share; close as of 2026-10-15.

## Checklist

### understandable: fail

- more than 2 net loss years

- Financial history: 8 years

- Years with a net loss: 8

Chart: Net income; fiscal year observations.

- FY2018: -$16M

- FY2019: -$37M

- FY2020: -$35M

- FY2021: -$52M

- FY2022: -$62M

- FY2023: -$38M

- FY2024: -$21M

- FY2025: -$210M

### moat: fail

- Years with nonpositive invested capital use equity plus debt and leases; positive earnings with no positive capital are shown above 100%.

- ROIC median below threshold

- ROIC worst years below threshold (more than 1 bad year allowed)

- ROIC, median of available years: -159.6%

- ROIC, second-lowest year: -941.6%

- Years with nonpositive capital: 3

- ROIC including acquisitions, ten-year median: -688.2%

Chart: ROIC excluding acquisitions; fiscal year observations.

- FY2018: -33.3%

- FY2019: -82.2%

- FY2020: -941.6%

- FY2021: -230.8%

- FY2022: -2072.6%

- FY2023: -88.4%

- FY2024: -432.1%

- FY2025: -69.3%

### economics: fail

- owner earnings cash conversion below threshold

- incremental invested capital return below threshold

- Cash conversion uses consolidated totals: No

- Owner earnings, five-year total: -$381M

- Net income, five-year total: -$383M

- Return on incremental invested capital: 0.0%

Chart: Owner earnings · five years; fiscal year observations.

- FY2021: -$52M

- FY2022: -$61M

- FY2023: -$38M

- FY2024: -$21M

- FY2025: -$210M

### management: fail

- buybacks unrelated to price (informational)

- ROIC first 3 years vs last 3 years: -82.2% vs -88.4%

- Per-share earnings: -34.48 to -36.08 (three-year endpoint medians)

- per-share value declined or ends nonpositive

- Management verdict uses per-share economic progress: Yes

- Ordinary dilution, 5-year annual growth: 6.2%

- Diluted shares, 5-year annual growth: 6.2%

- Per-share value change: -$1.61

- Per-share value, starting three-year median: -$34.48

- Per-share value, ending three-year median: -$36.08

- Buyback history: 0 years

- Debt-funded buybacks: No

- ROIC, first three-year median: -82.2%

- ROIC, last three-year median: -88.4%

Chart: Earnings per share; fiscal year observations.

- FY2018: -$15.60

- FY2019: -$36.13

- FY2020: -$34.48

- FY2021: -$51.22

- FY2022: -$60.63

- FY2023: -$36.08

- FY2024: -$18.53

- FY2025: -$153.95

### accounting: pass

- Sloan accruals: -78.0%

- Restructuring years, last five: 2

- Earnings backed by cash: Yes

- Accounting red flags: 0

- Goodwill and intangibles / equity: 0.00×

Chart: Sloan accruals; fiscal year observations.

- FY2018: -6.2%

- FY2019: -30.4%

- FY2020: 2.0%

- FY2021: 0.5%

- FY2022: -25.5%

- FY2023: -3.8%

- FY2024: -16.4%

- FY2025: -78.0%

## Holders

- [Andreas Halvorsen](https://gigainvestors.com/vg): tracked 13F investor; follow the investor page for holding quarter and amounts.

## Price story

Down 77% since Oct 2021 · net income USD -209.8M

Story as of 2026-10-16T09:58:38.805Z; price observation 2026-10-15.

### Net income · FY2025

net income USD -209.8M; source https://www.sec.gov/Archives/edgar/data/1800315/000119312526115922/dmra-20251231.htm; observed 2026-03-19.

- FY2018: -$16M 

- FY2019: -$37M 

- FY2020: -$35M 

- FY2021: -$52M 

- FY2022: -$62M 

- FY2023: -$38M 

- FY2024: -$21M 

- FY2025: -$210M 

## Owner memo

Memo as of 2026-10-16T08:06:05.509Z.

### Where the cash goes

Paid no dividends in 5 years.

- Source: https://eodhd.com/financial-apis/stock-etfs-fundamental-data-feeds/ (filed 2026-03-19); Dividend observations: [[2021,0],[2022,0],[2023,0],[2024,0],[2025,0]]. Zero only counted when supported by a complete cash-flow statement.

### Are managers owners

Insiders own 8.4% of the company.

- Source: https://eodhd.com/financial-apis/stock-etfs-fundamental-data-feeds/ (filed 2026-10-15); DMRA.US SharesStats.PercentInsiders = 8.431 percentage points; cache date 2026-10-15.

### What the price says

The price is 0.1 times net assets; cash earnings are negative.

- Source: https://eodhd.com/financial-apis/stock-etfs-fundamental-data-feeds/ (filed 2026-03-19); Closing price 18.74 USD; reporting-to-trading FX 1; FY2025 net assets per share 176.3603214955191; price multiple 0.10625972917880022. FY2025 cash earnings/share -153.92826878844906. Closing-price date 2026-10-15.

## Monthly share-price history (USD per share)

- 2020-10: $375.00 per share

- 2020-11: $382.75 per share

- 2020-12: $312.75 per share

- 2021-01: $309.75 per share

- 2021-02: $259.75 per share

- 2021-03: $151.88 per share

- 2021-04: $143.00 per share

- 2021-05: $132.75 per share

- 2021-06: $126.50 per share

- 2021-07: $107.25 per share

- 2021-08: $111.25 per share

- 2021-09: $89.75 per share

- 2021-10: $82.50 per share

- 2021-11: $70.50 per share

- 2021-12: $75.75 per share

- 2022-01: $60.00 per share

- 2022-02: $46.25 per share

- 2022-03: $55.00 per share

- 2022-04: $42.00 per share

- 2022-05: $32.75 per share

- 2022-06: $43.25 per share

- 2022-07: $40.25 per share

- 2022-08: $53.75 per share

- 2022-09: $47.25 per share

- 2022-10: $50.25 per share

- 2022-11: $39.25 per share

- 2022-12: $28.75 per share

- 2023-01: $57.50 per share

- 2023-02: $54.75 per share

- 2023-03: $49.75 per share

- 2023-04: $44.00 per share

- 2023-05: $54.50 per share

- 2023-06: $63.00 per share

- 2023-07: $77.00 per share

- 2023-08: $15.13 per share

- 2023-09: $18.00 per share

- 2023-10: $13.25 per share

- 2023-11: $15.75 per share

- 2023-12: $18.00 per share

- 2024-01: $15.30 per share

- 2024-02: $18.00 per share

- 2024-03: $19.50 per share

- 2024-04: $16.90 per share

- 2024-05: $15.20 per share

- 2024-06: $11.85 per share

- 2024-07: $14.10 per share

- 2024-08: $11.95 per share

- 2024-09: $12.15 per share

- 2024-10: $6.85 per share

- 2024-11: $5.30 per share

- 2024-12: $4.65 per share

- 2025-01: $4.96 per share

- 2025-02: $4.38 per share

- 2025-03: $3.10 per share

- 2025-04: $2.80 per share

- 2025-05: $3.07 per share

- 2025-06: $3.41 per share

- 2025-07: $3.29 per share

- 2025-08: $3.18 per share

- 2025-09: $3.72 per share

- 2025-10: $7.32 per share

- 2025-11: $17.78 per share

- 2025-12: $23.01 per share

- 2026-01: $26.24 per share

- 2026-02: $29.58 per share

- 2026-03: $25.90 per share

- 2026-04: $25.66 per share

- 2026-05: $24.88 per share

- 2026-06: $26.01 per share

- 2026-07: $28.99 per share

- 2026-08: $28.18 per share

- 2026-09: $21.28 per share

- 2026-10: $18.74 per share

## Annual estimated value (USD per share)

Historical values use today's bond yield for every fiscal year

Historical values use today's FX rate into trading currency for every fiscal year

Historical values use current restated fundamentals and current commodity classification; they are not point-in-time estimates

## Sources

[Original 10-K filing](https://www.sec.gov/Archives/edgar/data/1800315/000119312526115922/dmra-20251231.htm); period 2025-12-31, filed 2026-03-19.

Estimates depend on assumptions and are not guarantees or investment advice. Underlying data remains subject to its source licenses; public reading does not grant bulk redistribution rights.
← Companies

Damora Therapeutics

DMRA · US

Not a wonderful business

4 quality tests fail. A lower price would not fix the business.

Share price
$18.74
Quality tests
Fail
Annual history
8 years
Market value
$1.2B

The business

Where the cash goes
Are managers owners
What the price says

1. Is this a good business?

Evidence only; not required for Buy

8 loss years were recorded (limit 2).

8y median
-$37M
Worst year
-$210M
Latest · 2025
-$210M

Capital return excluding acquisitions: median -159.6% (minimum 15%), and the second-worst year -941.6% (minimum 10%).

8y median
-159.6%
Worst year
-2072.6%
Latest · 2025
-69.3%

Owners received -381.4 million over five years (must be positive), and new investment earned 0% (minimum 12%).

5y median
-$52M
Worst year
-$210M
Latest · 2025
-$210M

Per-share value fell from -34.48 to -36.08, comparing three-year medians at each end (must rise and stay positive).

8y median
-$36.11
Worst year
-$153.95
Latest · 2025
-$153.95

Profits were backed by cash: accruals were -78% of assets (limit 10%).

8y median
-11.3%
Worst year
2.0%
Latest · 2025
-78.0%

Profit record · fail 8 loss years in 8 (at most 2), three-year average owner earnings per share -69.2 USD. 8 loss years in the last 10; at most 2 allowed. Operating margin observed in 0 of the last 10 years; at least 5 needed. Three-year average owner earnings per share is not positive.

Revenue$0
$1.00$020182025
FY2021 · Revenue: $0; FY2022 · Revenue: $0; FY2023 · Revenue: $0; FY2024 · Revenue: $0; FY2025 · Revenue: $0
Revenue
Owner earnings-$210M
$1.00-$210M20182025
FY2018 · Owner earnings: -$14M; FY2019 · Owner earnings: -$36M; FY2020 · Owner earnings: -$35M; FY2021 · Owner earnings: -$52M; FY2022 · Owner earnings: -$61M; FY2023 · Owner earnings: -$38M; FY2024 · Owner earnings: -$21M; FY2025 · Owner earnings: -$210M
Owner earnings
Net cash / debt$258M
$258M$020182025
FY2018 · Net cash / debt: $31M; FY2019 · Net cash / debt: $11M; FY2020 · Net cash / debt: $163M; FY2021 · Net cash / debt: $99M; FY2022 · Net cash / debt: $59M; FY2023 · Net cash / debt: $33M; FY2024 · Net cash / debt: $13M; FY2025 · Net cash / debt: $258M
Net cash / debt
Diluted shares1.4M
1.4M020182025
FY2018 · Diluted shares: 1.0M; FY2019 · Diluted shares: 1.0M; FY2020 · Diluted shares: 1.0M; FY2021 · Diluted shares: 1.0M; FY2022 · Diluted shares: 1.0M; FY2023 · Diluted shares: 1.1M; FY2024 · Diluted shares: 1.2M; FY2025 · Diluted shares: 1.4M
Diluted shares
Prices 15 Oct 2026 · FY2025Original filing ↗ ·